Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Local Trials Could Delay India Dengvaxia Rollout By Three Years: Sanofi

Executive Summary

In the face of a growing outbreak in the country, Sanofi has urged India’s government to waive its insistence on local Phase III clinical trials for its vaccine to prevent dengue, warning that insistence on the development program could delay the Indian introduction of Dengvaxia by three years, amid rising medical need.

Advertisement

Related Content

Sanofi Optimistic On Dengue Vaccine In India Despite Waiver Blow

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC097282

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel